Pharmacokinetic studies with recombinant hirudin in dogs.
The knowledge of the pharmacokinetics of recombinant hirudin is essential for potential clinical use of this selective thrombin inhibitor. For detailed information about absorption, distribution and elimination, pharmacokinetic studies with recombinant hirudin were carried out in dogs. The plasma concentration time curve after intravenous injection could be best described by an open two-compartment model with first order kinetics. The subcutaneous application of recombinant hirudin produced anticoagulantly effective blood level for a prolonged period of time. Recombinant hirudin is distributed into the extracellular space. This is also found in nephrectomized dogs. Recombinant hirudin is eliminated through the kidneys by glomerular filtration in active form with a half-life of 72 minutes.
Nowak
G
G
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, GDR.
Markwardt
F
F
Fink
E
E
D000818:Animals; D004285:Dogs; D005343:Fibrinolytic Agents / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D006629:Hirudins / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D011994:Recombinant Proteins / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D005343:Fibrinolytic Agents; D006629:Hirudins; D011994:Recombinant Proteins